ArticleJournal of thoracic disease2025
Survival risk prediction nomogram for patients with resectable esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy followed by surgery: a retrospective study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and internal validation of a prognostic model for esophageal cancer liver metastases using the Surveillance, Epidemiology, and End Results database.Journal of thoracic disease · 2026Article
- Prognostic value of left gastric artery lymph node metastasis in patients with thoracic esophageal squamous cell carcinoma: a retrospective cohort study.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemoradiotherapy (NCRT) has long been considered the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC), but its long-term survival benefits remain limited and associated with potential safety concerns. The emergence of neoadjuvant immunochemotherapy (NICT) has shown encouraging short-term efficacy; however, evidence regarding its long-term outcomes and survival-related risk factors is still underexplored. This study aimed to evaluate survival outcomes of patients with resectable ESCC treated with NICT followed by surgery and to develop a nomogram for individualized survival risk prediction. Methods: Clinical data and follow-up information were retrospectively collected for 88 patients with ESCC who underwent NICT followed by McKeown esophagectomy. This study was conducted from January 2019 to December 2022 at Department of Thoracic Surgery, Guangdong Provincial People's Hospital. The median follow-up was 31.5 (range, 12-47) months. Statistical analysis was performed to evaluate clinical data and survival outcomes. Results: The study included 88 patients, equally divided by gender, with 44 males and 44 females. Multivariate regression analysis identified age, number of neoadjuvant treatment cycles, clinical primary tumor stage (cT), clinical lymph node stage (cN), and pathological lymph node stage (pN) as independent risk factors for survival in patients receiving NICT (P<0.05). A nomogram predictive model was constructed, demonstrating a high predictive value with an area under the receiver operating characteristic (ROC) curve of 0.927 [95% confidence interval (CI): 0.873-0.982]. Conclusions: NICT offers significant survival benefits for patients with resectable ESCC. The study identified age, neoadjuvant treatment cycles, cT, cN, and pN as independent risk factors impacting survival. The predictive model developed in this study can aid in selecting suitable postoperative adjuvant therapies, potentially enhancing treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.